Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$1.39 and traded as low as C$1.18. Oncolytics Biotech shares last traded at C$1.21, with a volume of 144,265 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a report on Thursday, November 14th.
Oncolytics Biotech Price Performance
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
- Five stocks we like better than Oncolytics Biotech
- The 3 Best Fintech Stocks to Buy Now
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- How Do Stock Buybacks Affect Shareholders?
- 3 Best Fintech Stocks for a Portfolio Boost
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.